Stock Movers Novo and Dayforce Jumps; Apple Headset
Aug 18, 2025
Novo Nordisk's shares surged following FDA approval for its weight-loss drug Wegovy to treat liver disease. Meanwhile, Dayforce's stock rose amid rumors of a buyout by Thoma Bravo, potentially transforming the company into a private entity. On the tech front, Apple's Vision Pro headset faces sales challenges due to its high price and unconvincing features, raising concerns about its future in the market. These developments highlight the dynamic movements in the market and the strategies companies are employing.
AI Snips
Chapters
Transcript
Episode notes
Host's Personal Wegovy Anecdote
- John Tucker mentions a personal BMI check and connects it to Wegovy's popularity among people he knows.
- He frames Wegovy's expanded approval as a notable development after discussing side effects and usage.
Wegovy Approval Expands Market
- Novo Nordisk's Wegovy gained U.S. approval for treating MASH, expanding its market beyond weight loss.
- The approval gives Novo an edge over Eli Lilly and could revive momentum after early-year losses.
Private-Equity Interest In Dayforce
- Thoma Bravo is reportedly in talks to take Dayforce private, reflecting buyout interest in enterprise HR software.
- Dayforce's shares fell from a 2021 peak despite revenue growth and improved profitability since 2021.